Trusted Resources: Education
Scientific literature and patient education texts
Cell-Penetrating Peptide-Conjugated Morpholino Rescues SMA in a Symptomatic Preclinical Model
source: Molecular therapy : the journal of the American Society of Gene Therapy
year: 2021
authors: Bersani M,Rizzuti M,Pagliari E,Garbellini M,Saccomanno D,Moulton HM,Bresolin N,Comi GP,Corti S,Nizzardo M
summary/abstract:Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of infant mortality. Recently approved SMA therapies have transformed a deadly disease into a survivable one, but these compounds show a wide spectrum of clinical response and effective rescue only in the early stages of the disease. Therefore, safe, symptomatic-suitable, non-invasive treatments with high clinical impact across different phenotypes are urgently needed. We conjugated antisense oligonucleotides with Morpholino (MO) chemistry, which increase SMN protein levels, to cell-penetrating peptides (CPPs) for better cellular distribution. Systemically administered MOs linked to r6 and (RXRRBR)XB peptides crossed the blood-brain barrier and increased SMN protein levels remarkably, causing striking improvement of survival, neuromuscular function, and neuropathology, even in symptomatic SMA animals. Our study demonstrates that MO-CPP conjugates can significantly expand the therapeutic window through minimally invasive systemic administration, opening the path for clinical applications of this strategy.
organization: Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy.DOI: 10.1016/j.ymthe.2021.11.012
read more
Related Content
-
Children’s Hospital of The King’s Daughters – Spinal Muscular Atrophy CenterThe development of novel treatments for ...
-
Kristin J. Krosschell, DPTKristin J. Krosschell, DPT is the Profes...
-
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
-
Once-Daily Risdiplam Beneficial in Patients With Types 2 and 3 SMA: LancetOnce-Daily Risdiplam is beneficial in pa...
-
Improvement in Fine Manual Dexterity in Children With Spinal Muscular Atrophy Type 2 After Nusinersen Injection: A C...Although nusinersen has been demonstrate...
-
Spinal Muscular Atrophy 2019: SMA Pathophysiology, Diagnosis and Clinical Presentationshttps://www.youtube.com/watch?v=cUuWue8M...
-
Risdiplam for the Use of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is one of ...